New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT03065387
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This early-stage trial tests the safety and best dose of the drug neratinib when combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene mutations or amplifications. The study enrolls 93 participants whose cancers have not responded to standard treatments. The goal is to find tolerable doses and understand side effects, not yet to prove the combinations work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- neratinib combined with everolimus, palbociclib, or trametinib
- What this could lead to
- If successful, this could point toward new combination treatments for advanced cancers with certain gene changes that have stopped responding to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The combinations may cause significant side effects and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart resistant lung cancer?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors